HLA-A MHC Tetramer Technology: A Multidimensional Application Platform for Antigen-Specific T Cell Detection and Immunotherapy Research

Author: Senior Product Manager of UA Views：531

The ongoing global public health crisis triggered by SARS-CoV-2 has propelled international academic and industrial communities to intensify efforts in elucidating the fundamental biological properties of the novel coronavirus, as well as accelerating the development of preventive vaccines and therapeutic interventions. Within this context, research focused on antigen-specific T cells has emerged as a pivotal frontier in immunology. This field not only provides critical immunological response indicators for vaccine development but also holds substantial scientific significance across multiple domains, including disease prognosis monitoring, deciphering viral infection mechanisms, and advancing cancer immunotherapy strategies.

Recent Advances
Product Information

Recent Advances

HLA - A MHC Tetramer

The global public health crisis caused by SARS - CoV - 2 continues to evolve. It has accelerated the efforts of the international academic and industrial communities to study the basic biological characteristics of the novel coronavirus, as well as to develop preventive vaccines and therapeutic drugs.

In this context, research on antigen - specific T cells has become a cutting - edge area in immunology. It not only provides key immune response indicators for vaccine development but also shows great scientific value in disease prognosis monitoring, viral infection mechanism analysis, and tumor immunotherapy.

As a breakthrough tool in detection immune technology, MHC tetramer technology enables the direct visualization of antigen - specific T cells. The principle of this technology is based on the specific recognition of T cell receptors (TCRs) for MHC - antigen peptide complexes on the surface of target cells or antigen - presenting cells. However, the interaction between them in their natural state has low binding affinity and is prone to dissociation.

MHC tetramers, through bio - orthogonal chemical methods, assemble four MHC class I molecules combined with specific antigenic peptides into a single - unit complex in a spatially oriented manner. This creates a fluorescent - labeled complex with quadrivalent binding capacity. The multivalent binding mode significantly enhances the stability of the interaction with TCRs. Through synergistic effects at multiple sites, it amplifies T cell recognition signals. This overcomes the sensitivity thresholds of traditional detection methods and provides a precise quantitative analysis tool for studying the cellular and molecular mechanisms of adaptive immune responses.

The core advantage of this technology is its ability to directly reflect the epitope specificity of functional T cells. During the vaccine development phase, it can accurately evaluate the immunogenicity of candidate antigens. In clinical trials, it can dynamically monitor the longevity and breadth of cellular immune responses. Meanwhile, it also offers support for the development of personalized tumor immunotherapy strategies by providing biomarkers.

With the integrated development of single - cell sequencing technology and multimodal flow cytometry, MHC tetramer technology is continuously expanding its application in immune mapping, disease prognosis prediction, and the development of new immunotherapies.

MHC Tetramer Application Fields:

Viral Infection Research - Precise detection of virus - specific T cell immune responses and analysis of pathogenesis;

Vaccine Design and Efficacy Monitoring Ant -igen epitope screening and optimization, immunogenicity evaluation, and the construction of safety assessment systems;

Cellular Immune Quantitative Analysis - Combined with flow sorting to technology achieve in - vitro expansion of functional T cell subsets and functional analysis;

Antigen Epitope Spectrum Research - Systematic screening and identification of high - affinity immunodominant epitopes;

Tumor Immunotherapy - Precise targeting of tumor - specific antigenic epitopes and the development of cell - based therapeutic strategies;

Pe -ptide MHC Interaction Research - Quantitative detection and characterization of affinity and kinetic parameters.

Flex - T™ Technology:

Flex - T™, as a new - generation tool for antigen - specific T cell research, innovatively uses ultraviolet - light - controlled peptide exchange technology. This technology platform is based on pre - loaded ultraviolet - sensitive MHC monomers. Upon irradiation with specific wavelength ultraviolet light, the pre - loaded peptides rapidly degrade. This enables efficient replacement target of peptides with MHC - binding grooves. This modular design breaks through the traditional technology's reliance on pre - synthesized peptides. It establishes an open peptide screening platform, supporting rapid functional validation of any candidate peptide segment (meeting the basic affinity requirements for MHC binding). It provides revolutionary technical support for tracking T cell immune responses during vaccine development and discovering new immunotherapeutic targets.

Human Class I Peptide Exchange ELISA Kit:

This kit is an innovative pre - coated enzyme linked - immunosorbent assay (ELISA) detection platform. It is specially designed for antigen peptide affinity assessment and validation of ultraviolet - mediated peptide exchange efficiency. core Its advantages are reflected in three aspects: enabling high - throughput screening of candidate peptide segments with ideal MHC class I molecule binding characteristics; supporting immediate peptide replacement efficiency detection through modular design; and significantly optimizing the experimental process. There is no need to pre - synthesize multiple tetramer complexes to complete functional validation. It is cost - effective,ally operation flexible, and has controllable experimental timelines.

Detection Principle:

A standardized 96 - well ELISA plate has been pre - coated with mouse a - derived monoclonal antibody against human β2 - microglobulin, constructing a specific capture interface.
Horseradish peroxidase (HRP) - labeled streptavidin can form a covalent bond with biotin - modified HLA class I molecule monomers.
Through a double - antibody sandwich method, it captures intact HLA class I molecule complexes (α chain/β2 - microglobulin/antigenic peptide trimer). This ensures that the detection signal strictly depends on the spatial conformational integrity of the complex.
The peptide binding affinity is positively correlated with the detection signal intensity. High - affinity peptide replacement generates stable complexes, producing strong a signal response. In contrast, medium - or low - affinity peptide replacement leads to signal attenuation or non - detectability.

This technology system provides a key experimental evidence chain for antigenic epitope screening, T cell immune response research, and the development of new immunotherapeutic targets by quantitatively analyzing the enzyme - linked signal output after ultraviolet - induced peptide replacement.

Related Products:

Disease Category	Product Name	Antigen	Sequence	MHC	Position	Product Number
EBV	HLA-A*0201/YLELLVWRL-PE Labelled Tetramer	EBV.LMP1	YLELLVWRL	HLA-A*0201	125-133	UA089001
EBV	HLA-A*0201/YLQQNWTL-PE Labelled Tetramer	EBV.LMP1	YLQQNWTL	HLA-A*0201	159-167	UA089003
EBV	H-2Db(b)/RAHY-NIVTF-PE Labelled Tetramer	HPV16.E7	RAHYNIVTF	H-2Db	49-57	UA089002
HPV	H-2K(b)/EVYDFA-FRQL-PE Labelled Tetramer	HPV16.E6	EVYDFARDL	H-2Kb	48-57	UA089004
HPV	HLA-A*0201/KLP-DLCTL-PE Labelled Tetramer	HPV18.E6	KLPDCTL	HLA-A*0201	13-21	UA089005
HPV	HLA-A*0201/KLTNT-GLYQL-PE Labelled Tetramer	HPV18.E6	KLTNTGLYNL	HLA-A*0201	92-101	UA089006
HPV	HLA-A*0201/TLODIVIHL-PE Labelled Tetramer	HPV18.E7	TLODIVIHL	HLA-A*0201	7~15	UA089007
HPV	HLA-A*0201/QFLNTL-FV-PE Labelled Tetramer	HPV18.E7	QFLNTLFSV	HLA-A*0201	88-97	UA089008
HPV	HLA-A*1101/GVNHQLPAR-PE Labelled Tetramer	HPV18.E7	GVNHQLPAR	HLA-A*1101	43-52	UA089009
Influenza A Virus	H-2D(b)/ASNENMETM-PE Labelled Tetramer	Flu.NP	ASNENMETM	H-2Db	366-374	UA089010
Influenza A Virus	H-2K(d)/TYQR-TRALY-PE Labelled Tetramer	Flu.NP	TYQRTRALY	H-2Kd	147-155	UA089011
Influenza A Virus	H-2D(b)/ASNEN-MDTM-PE Labelled Tetramer	Flu.NP	ASNENMDTM	H-2Db	366-374	UA089012
LCMV	H-2D(b)/KAVYNFATM-PE Labelled Tetramer	GP 33	KAVYNFATM	H-2Db	33-41	UA089013
LCMV	H-2D(b)/FQPGQGFVK-PE Labelled Tetramer	LCMV NP	FQPGQGFVK	H-2Db	396-404	UA089014
Tumor-related	HLA-A*1101/VVGADGVK-PE Labelled Tetramer	KRAS	VVGADGVK	HLA-A*1101	7~16	UA089015
Tumor-related	HLA-A*1101/VVGAGVGK-PE Labelled Tetramer	KRAS	VVGAGVGK	HLA-A*1101	7~16	UA089016
Tumor-related	HLA-A*0201/KLVVGAGV-PE Labelled Tetramer	KRAS	KLVVGAGV	HLA-A*0201	5~14	UA089017
Tumor-related	HLA-A*0201/SLLMWITQC-PE Labelled Tetramer	NY-ESO1	SLLMWITQC	HLA-A*0201	157-165	UA089018
Melanoma	HLA-A*0201/LMWITQCFL-PE Labelled Tetramer	NY-ESO2	LMWITQCFL	HLA-A*0201	159-167	UA089019
Melanoma	H-2Db(b)/MMFPNA-P1-PE Labelled Tetramer	WT1	RMFPNAPL	H-2Db	126-134	UA089020
Melanoma	HLA-A*0201/CMTWV-PE Labelled Tetramer	WT2	CMTWVNMDM	HLA-A*0201	235-243	UA089021
Melanoma	HLA-A*1101/KTCQRKSF-PE Labelled Tetramer	WT3	KTCQRKSF	HLA-A*1101	386-394	UA089022
Ovarian Cancer	H-2K(b)/SINFEKL-PE Labelled Tetramer	OVA	SINFEKL	H-2Kb	257-264	UA089023

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next